Medtronic PLC vs Oatly Group AB - ADR — how do they compare? Medtronic PLC trades at $88.26 (market cap $112.24B), while Oatly Group AB - ADR trades at $10.35 (market cap $330.93M). The key difference: Medtronic PLC is far larger — about 339.2× Oatly Group AB - ADR's market cap, and Medtronic PLC pays a 3.28% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Oatly Group AB - ADR for 18 Days on average.
| MDT | OTLY | |
|---|---|---|
Market Cap | $112.24B | $330.93M |
Volume | 105,663,236 | 68,708 |
Sector | Health | Consumer Staples |
52-Week High | $105.35 | $15.91 |
52-Week Low | $73.75 | $8.03 |
Typical Hold Time | 63 Days | 18 Days |
Enterprise Value | $131.58B | $835.34M |
Dividend Yield | 3.28% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
OTLY trades at $10.37, down 1.33% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. Fundamentally, the company shows improving revenue growth ($862M in 2025, projected $925M in 2026) and narrowing losses, though it remains unprofitable with negative cash flow. Analyst sentiment is divided with a $12.28 consensus target, representing 18% upside potential from current levels.
The outlook suggests cautious optimism as Oatly demonstrates operational improvements and revenue acceleration, but significant risks remain including persistent negative cash flow, high debt levels, and competitive pressures in the plant-based beverage market. The stock offers potential for recovery if the company can achieve its projected path toward profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →